Conmed (CNMD) reported $327.05 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 30.4%. EPS of $1.06 for the same period compares to $0.42 a year ago. The reported revenue represents a surprise of -1.77% over the Zacks Consensus Estimate of $332.94 million. With the consensus EPS estimate being $1.11, the EPS surprise was -4.51%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

Conmed (CNMD) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -4.51%. A quarter ago, it was expected that this medical technology company would post earnings of $0.83 per share when it actually produced earnings of $0.90, delivering a surprise of 8.43%. Over the last four quarters, ...

业绩总结 - 公司在2023年第四季度的总收入为3.27亿美元，同比增长30.4%[9] - 公司在2023年第四季度的调整后每股收益为1.06美元，同比增长152.4%[9] - 公司在2023年全年的总收入为12.45亿美元，同比增长19.1%[10] - 公司在2023年全年的调整后每股收益为3.45美元，同比增长30.2%[10] - 2024年全年营收预计为13.4亿至13.65亿美元，增长8%至10%[12] - 调整后的毛利率预计将提高100至150个基点[12] - 调整后的现金每股收益预计为4.30至4.40美元，增长25%至28%[12] 新技术和市场扩张 - 公司在墨西哥奇瓦瓦工厂获得自2015年以来的清洁工业认证[13] - 公司在纽约乌提卡工厂和奇瓦瓦工厂100%采用LED照明[13] 市场策略 - 公司强调解决医疗客户未满足需求，以增加市场份额[14]

Key Points CONMED shares dove 10% last week, retreating below the $100.00 level in an apparent bout of profit taking on one of the market’s hottest groups. The company is expected to have generated approximately $332 million in fourth quarter sales with EPS forecast to jump 164% year-over-year to $1.11. Even if the "Ozempic effect" is large, it will likely have an insignificant impact on CONMED’s overall financial results since the company provides products for many procedures other than bariatric surgery. ...

财务数据 - Conmed (CNMD)预计在即将发布的季度报告中每股盈利为$1.11，同比增长164.3%[1] - 分析师预计收入将达到$3.3294亿，同比增长32.7%[1] 公司关键指标预测 - 分析师对公司的关键指标进行了预测，包括'Net Sales- Orthopedic Surgery'、'Net Sales- General Surgery'、'Net Sales- Single-use Products'和'Net Sales- Capital Products'[6][7][8][9]

CONMED Corporation (NYSE:CNMD) Q3 2023 Earnings Conference Call October 25, 2023 4:30 PM ET Company Participants Curt Hartman – President and Chief Executive Officer Todd Garner – Executive Vice President and Chief Financial Officer Conference Call Participants Vik Chopra – Wells Fargo Robbie Marcus – J.P. Morgan Rick Wise – Stifel Matt O’Brien – Piper Sandler Kristen Stewart – CL King Carolyn Huszagh – Bank of America Operator Thank you for standing by. And welcome to CONMED’s Q3 Fiscal Year 2023 Earnings ...

业绩总结 - 公司在2023年第三季度实现了10.7%的年度收入增长，达到了3.046亿美元[9] - 公司调整后的每股收益为0.90美元，同比增长16.9%[9] - 公司预计2023年全年营收将达到12.4亿美元，调整后的每股收益为3.55美元[11] 公司信息 - Chihuahua, Mexico工厂自2015年以来持有清洁工业认证[12] - Utica, New York工厂获得ISO 14001认证[12] - Utica和Chihuahua工厂100%使用LED照明[12] - 全球员工中53%为女性[12] - 董事会中33%为女性[12] - 董事会委员会主席每五年轮换一次[12] - 员工参与度达到98%[12] - 董事会服务任期限制为12年[12] 公司定位 - CONMED专注于解决医疗客户未满足的需求[13]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2023 001-39218 CONMED CORPORATION (Exact name of the registrant as specified in its charter) Delaware 16-0977505 (State or other jurisdiction of incorporation or organization) (I ...

CONMED Corporation (NYSE:CNMD) Q2 2023 Earnings Conference Call July 26, 2023 4:30 PM ET Company Participants Curt Hartman - Chairman, President, and CEO Todd Garner - EVP and CFO Conference Call Participants Robert Marcus - JPMorgan Rick Wise - Stifel Matthew O'Brien - Piper Sandler Vik Chopra - Wells Fargo Matthew Mishan - KeyBanc Young Li - Jefferies Kristen Stewart - C.L. King Mike Matson - Needham & Company Operator Before the conference call begins, let me remind you that during this call, management ...

Investor Presentation Q2 2023 Earnings Call ...